[Application of ultrathin transnasal gastroscopy in percutaneous endoscopic gastrostomy].

OBJECTIVE: To assess the application of ultrathin transnasal gastroscopy in transnasal percutaneous endoscopic gastrostomy (nPEG) in patients with trimus and/or pharyngeal narrowing. METHODS: Nine consecutive patients underwent PEG with the Introducer method using conventional gastroscopy (5 cases) or ultrathin transnasal gastroscopy (4 cases). Among the 4 patients undergoing nPEG, 3 received radiotherapy for nasopharyngeal cancer, including two with trimus and one with trimus and pharyngeal narrowing. The procedure time, safety, discomfort and complications in these cases were compared and evaluated. RESULTS: The average procedure time of PEG was 17+/-3.5 min in conventional gastroscopy group and 17+/-3.1 min in nPEG group. No complications were observed in these patients, but the patients in nPEG group reported less discomfort associated with the procedure. CONCLUSIONS: Ultrathin transnasal gastroscopy reduces the discomfort of the procedure and is safer than conventional gastroscopy for PEG, especially in patients with trimus and/or pharyngeal narrowing.

[Evaluation on reducing effect of eye drop on herpes simplex virus-I in vitro].

OBJECTIVE: To observe the effect of herbal eye drop Reduqing (clearing toxic heat) on herpes simplex virus (HSV) on the cytopathic effect in cell culture in vitro. METHODS: The maximal non-toxic Reduqing eye drop concentration added to cell culture infected with 100 and 10TCID50 of herpes simplex virus? (HSV-1) to observe the inhibitory effect of the medicine on HSV-I induced cytopathic effect. RESULTS: The Reduqing eye drop at maximal non-toxic concentration could obviously inhibit the cytopatic effect induced by 100TCID50 and 10TCID50 HSV-I. No statistically significant difference was found when compared with 0.1% acyclovir eye drop (P>0.05), on cytopathic effect occurred with boty eye drops. However, there was significant difference when compared with control group(P<0.05). The inhibitory effect of concentrations of Reduqing at 500,000 and 63,000 microg/L was stronger than that of 2,000,000 and 1,000,000 microg/L (P 0.01). The maximal tolerable concentration of Reduqing eye drop by the cell was 2,000,000 microg/L (1:80 dilution), which was higher than that of 5,000 microg/L(1:400 dilution) acyclovir eye drop. CONCLUSIONS: These results suggest that Reduqing eye drop could markedly inhibit the cytopathic effects caused by HSV-I. The Reduqing eye drop showed remarkably low toxic effect to the cells as compared to acyclovir eye drop.